File:SputnikVEfficacy001.svg · Wikimedia Commons · See Wikimedia Commons
Gam-COVID-Vac
Sign in to saveAlso known as Sputnik V, Gamaleya Research Institute COVID-19 vaccine candidate, Gam-COVID-Vac Lyo, Russian vaccine, Sputnik vaccine, Russian Sputnik vaccine
Russian viral vector vaccine based on human adenovirus
Gam-COVID-Vac is a Russian COVID-19 vaccine that uses modified human adenoviruses as vectors to deliver genetic instructions to the body's cells. It represents one of several different technological approaches countries developed to create coronavirus vaccines during the pandemic.
AI-generated from the Wikipedia summary — may contain errors.
Official website
Sputnik V - the first registered vaccine against COVID-19. Official website vaccine against coronavirus Sputnik V.
Official website vaccine against coronavirus Sputnik V. The first registered vaccine against COVID-19 Sputnik V.
sputnikvaccine.com →Link to the official site · 31,215 chars · not written by Vinony
Wikidata facts
- Named after
- victory
- Country of origin
- Russia
- Official website
- sputnikvaccine.com
- Image
- Вакцина Спутник V.jpg
Show 9 more facts
- vaccine for
- COVID-19
- Commons category
- Sputnik V
- nickname
- Sputnik V
- route of administration
- intramuscular injection
- announcement date
- 2020-05-00
- price
- 10
- on focus list of Wikimedia project
- WikiProject COVID-19
- social media followers
- 1017456
- native label
- Gam-COVID-Vak
Sources (10)
via Wikidata · CC0
~40 min read
Encyclopedic overview
Sputnik V (Russian: Спутник V, the brand name from the Russian Direct Investment Fund or RDIF) or Gam-COVID-Vac (Russian: Гам-КОВИД-Вак, the name under which it is legally registered and produced) is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
Gam-COVID-Vac was initially approved for distribution in Russia and then in 59 other countries (as of April 2021) on the preliminary results of Phase I–II studies eventually published on 4 September 2020. Approval in early August of Gam-COVID-Vac was met with criticism in mass media and discussions in the scientific community as to whether approval was justified in the absence of robust scientific research confirming safety and efficacy. A large-scale Brazilian study from Dec. 2020 to May 2021 confirmed its effectiveness and safety, as of Oxford–AstraZeneca's, i.e. above Sinopharm BIBP's.
Excerpted from Wikipedia’s “Gam-COVID-Vac” article, available under the CC BY-SA 4.0 licence.